This legal form of company strengthens its position as a full-service CDMO and ensures its place as an industry leader.
Rentschler Biotechnologie has announced that the company has successfully transitioned into a European corporation (SE) with entry into the German commercial register on 1 October 2017. The company is operating as Rentschler Biopharma SE with immediate effect. There will be no operational changes for clients or employees of the family-owned company due to the transition.
“With our transition to Rentschler Biopharma SE, we emphasize our long-term international corporate identity, while the core business remains unaffected. In future, this legal form of company strengthens our position as a full-service CDMO and ensures our place as a leader in this industry,” commented Prof. Dr Nikolaus F. Rentschler, Owner of Rentschler Biopharma SE. “Our proven service offering along the entire value chain – from bioprocess development through biomanufacturing to fill and finish of biopharmaceuticals – remains unchanged. This also applies to our company sites and manufacturing facilities as well as the existing client relations and importantly their contact persons.”
Over the recent years, Rentschler Biopharma has grown considerably and invested constantly in facilities so that capacities have more than doubled. With the expansion of our facilities, a continually growing number of employees has also been added to the company. About 200 employees have been recruited in all business segments during the past year and a half. In the current fiscal year, over 120 additional positions are to be filled.Read More
SIRION Biotech and Vibalogics partner to offer complete AAV services18 Oct 2017
STA Pharmaceutical to open new transition metal catalysis center in Changzhou, China18 Oct 2017
New European Council of regulatory professionals set to shape and support the profession18 Oct 2017